Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, In...
20374 Seneca Meadows Parkway
Germantown, MD 20876
Founded in 1998
Intrexon Corporation Presents at Stifel Healthcare Conference 2015, Nov-18-2015 10:15 AM
Nov 16 15
Intrexon Corporation Presents at Stifel Healthcare Conference 2015, Nov-18-2015 10:15 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Samuel E. Broder, Senior Vice President of Health Sector.
Intrexon Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 9 15
Intrexon Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company has posted total revenues of $53,367,000 against $21,197,000 a year ago. Operating loss was $7,916,000 against $15,047,000 a year ago. Loss before income tax was $39,952,000 against $53,862,000 a year ago. Net loss was $39,029,000 against $53,862,000 a year ago. Net loss attributable to Intrexon was $38,213,000 or $0.34 basic and diluted share against $52,725,000 or $0.53 basic and diluted share a year ago. LBITDA was $34,029,000 against $49,545,000 a year ago. Adjusted EBITDA was $3,769,000 or $0.03 diluted per share against $1,594,000 or $0.02 diluted per share a year ago.
For the nine months, the company has posted total revenues of $132,107,000 against $40,838,000 a year ago. Operating loss was $112,469,000 against $51,001,000 a year ago. Loss before income tax was $53,913,000 against $103,525,000 a year ago. Net loss was $54,719,000 against $103,548,000 a year ago. Net loss attributable to Intrexon was $51,779,000 or $0.47 basic and diluted share against $100,653,000 or $1.02 basic and diluted share a year ago. LBITDA was $37,973,000 against $93,691,000 a year ago. Adjusted EBITDA was $43,556,000 or $0.39 diluted per share against $8,754,000 or $0.09 diluted per share a year ago.
Intrexon Corporation to Report Q3, 2015 Results on Nov 09, 2015
Nov 3 15
Intrexon Corporation announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Nov 09, 2015